“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...
Obstructive sleep apnea occurs when a person’s upper airway ... the condition by reducing body weight, according to the FDA. The move comes as weight-loss medications have garnered immense ...
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
Obese mice whose fat cells were genetically altered to produce an increased amount of the glucose-dependent insulinotropic ...
After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...